Stay updated with breaking news from Exposure Registry. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Detailed results from SURMOUNT-4, which showed Zepbound™ (tirzepatide) injection achieved superior mean percent change in body weight compared...
People who were randomized to placebo following the lead-in period experienced mean weight regain of 14.8% at 88 weeks, indicating Zepbound led to sustained weight loss compared to placebo Full results from the SURMOUNT-4 study were published in The Journal of the American Medical Association INDIANAPOLIS, Dec. 11, 2023 /PRNewswire/ — Detailed results from SURMOUNT-4, […]
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Zepbound™ (tirzepatide) injection is now available. Zepbound is indicated for adults...
Adults taking Zepbound in a clinical trial lost on average 48 lb. at the highest dose Zepbound is the first and only approved treatment activating two incre ...
Adults taking Zepbound in a clinical trial lost on average 48 lb. at the highest dose Zepbound is the first and only approved treatment activating two incretin hormone receptors, GIP and GLP-1, to...